Income and wealth concentration follows the ebbs and flows of the business cycle in America.

Amy Hamilton

2019-04-23 19:45:00 Tue ET

Income and wealth concentration follows the ebbs and flows of the business cycle in America. Economic inequality not only grows among people, but it also grows among companies. A recent McKinsey study shows that only 10% of 5,750 public and private companies (each with over $1 billion in total revenue) account for 80% of their net profits. These top 10% superstar companies can create almost as much firm value as the bottom 10% companies destroy on an annual basis. The top 10% superstar wealth creation has grown 1.6 times in the past 20 years, whereas, the bottom 10% value erosion has risen only 1.5% in the same time frame. One major root cause of this wealth divergence is the corporate focus on key intangible assets and intellectual properties such as patents, trademarks, databases, robots, cloud services, and software solutions. These intangible assets thus serve as affordable competitive moats for the top 10% superstar companies. These top 10% superstar firms spend about 2 to 3 times more on R&D than their peers and hence account for 70% of all R&D expenditures in Corporate America as of early-2019.

However, the top 10% superstar companies are less likely to maintain their product market dominance because half of the superstar companies lose their competitive advantages over the course of one single real business cycle (or about 7-9 years). For this reason, tougher antitrust scrutiny may not be the panacea for addressing the economic implications of anti-competitive clout in tech titans (Apple, Amazon, Alibaba, Facebook, Google, Microsoft, Nvidia, and Twitter), big biotech bellwethers (Johnson & Johnson, Pfizer, Merck, Abbot, Amgen, and Bristol-Myers Squibb etc), and telecoms (Verizon, AT&T, Sprint, and T-Mobile etc). Weaker product market competition may help explain why U.S. productivity growth, capital investment, and wage growth continue to stagnate in recent years.

This dilemma often manifests in the 7%-8% increase in average markups over the marginal costs for more than 900,000 firms from 2000 to early-2019 in accordance with a recent IMF staff report. The higher markups significantly correlate with lower capital investment, subpar wage growth, and less disposable income for the typical U.S. household. In other words, these markups represent the inadvertent social price of market power. Overall, it is important for regulators to help promote greater market competition in several industries such as technology, energy, medicine, air transport, and telecommunication etc.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Facebook CEO Mark Zuckerberg testifies in Congress to rise up to the challenge of public outrage.

Rose Prince

2018-04-07 09:36:00 Saturday ET

Facebook CEO Mark Zuckerberg testifies in Congress to rise up to the challenge of public outrage.

Facebook CEO Mark Zuckerberg testifies in Congress to rise up to the challenge of public outrage in response to the Cambridge Analytica data debacle and use

+See More

State, society, and the narrow corridor to liberty

Joseph Corr

2023-09-28 08:26:00 Thursday ET

State, society, and the narrow corridor to liberty

Daron Acemoglu and James Robinson show a constant economic tussle between society and the state in the hot pursuit of liberty. Daron Acemoglu and James R

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Angus Deaton analyzes the correlation between health and wealth in light of the economic origins of inequality worldwide.

James Campbell

2023-04-21 12:39:00 Friday ET

Angus Deaton analyzes the correlation between health and wealth in light of the economic origins of inequality worldwide.

Angus Deaton analyzes the correlation between health and wealth in light of the economic origins of inequality worldwide. Angus Deaton (2015)  

+See More

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most corporations.

Daisy Harvey

2023-07-28 11:28:00 Friday ET

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most corporations.

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most U.S. public corpor

+See More

The Chinese new star board launches for tech firms to list at home.

Daphne Basel

2019-07-09 15:14:00 Tuesday ET

The Chinese new star board launches for tech firms to list at home.

The Chinese new star board launches for tech firms to list at home. The Nasdaq-equivalent new star board serves as a key avenue for Chinese tech companies t

+See More